英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
aacompaignier查看　aacompaignier　在百度字典中的解释百度英翻中〔查看〕
aacompaignier查看　aacompaignier　在Google字典中的解释Google英翻中〔查看〕
aacompaignier查看　aacompaignier　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Blocking PD-L1–PD-1 improves senescence surveillance and ageing . . .
    Therefore, to control immunotherapy in age-related diseases, it may be necessary to optimize the use of each treatment by taking into consideration the balance of enhanced immune clearance, the
  • Management of toxicities from immunotherapy: ESMO Clinical Practice . . .
    Primary hypothyroidism is the most common IR-endocrinopathy and occurs in ∼6%-9% of patients treated with anti-PD-1 and or anti-programmed death-ligand 1 (PD-L1) therapy, in 4% treated with anti-CTLA-4 therapy and in ≤16% treated with anti-PD(L)1–anti-CTLA-4 combination therapy 19 It may be preceded by a hyperthyroid state, which may be
  • Management of Immune-Related Adverse Events in Patients Treated With . . .
    Although the frequency of colitis reported in the literature ranges from 8% to 27%, the incidence of diarrhea is as high as 54% in patients treated with anti–CTLA-4 antibodies, 64,65 especially in patients who receive anti–CTLA-4 and anti–PD-1 combination therapy 66 GI toxicity is less common with anti–PD-1 monotherapy, with the
  • Severe autoimmune hemolytic anemia following immunotherapy with . . .
    The patient received a transfusion of a red blood cell concentrate and systemic treatment with prednisolone 80 mg per os (p o ), which was tapered over the following weeks Treatment resulted in an increase in hemoglobin from 7 3 to 10 7 g dL within four weeks
  • Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 . . .
    Importance: Agents targeting programmed cell death 1 (PD-1) PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas The incidence and spectrum of chronic immune-related adverse events (irAEs) have not been well defined Objective: To determine the incidence, time course, spectrum, and associations
  • The therapeutic potential of PD-1 PD-L1 pathway on immune-related . . .
    PD-1 PD-L1 pathway has been demonstrated to mediate immune suppression in both innate and adaptive immune systems, and thus it is essential for modulation of immune responses and inflammation as well as for maintenance of immune homeostasis and self-tolerance [6] As shown in Fig 1, the binding of PD-L1 to PD-1, on activated T cells and B cells, leads to T cell and B cell exhaustion, which is
  • Immune-checkpoint inhibitors: long-term implications of toxicity
    The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer treatment, enabling the possibility of long-term survival in patients with metastatic disease, and providing
  • Long-Term Survival, Quality of Life, and Psychosocial Outcomes in . . .
    Immune checkpoint inhibitors have become a standard of care option for the treatment of patients with advanced melanoma Since the approval of the first immune checkpoint (CTLA-4) inhibitor ipilimumab in 2011 and programmed death-1 (PD-1) blocking monoclonal antibodies pembrolizumab and nivolumab thereafter, an increasing proportion of patients with unresectable advanced melanoma achieved long
  • Long-term immune-related adverse events under PD-1 inhibitors: a . . .
    Long-term IRAE, mostly grades 1-2, occurred in 52 patients (43%) Long-term IRAE led to 5 hospitalizations (4%) of which 4 were grades 3-4 Among patients with long-term IRAE, 45 patients (87%) previously experienced IRAE within the first 2 years of anti-PD1 and 29 patients (56%) experienced multiple IRAE
  • New and Worsening Long-term Immune-Related Adverse Events with . . . - PubMed
    Although much is known regarding irAEs that occur early during treatment, data on the long-term toxicity profile of these agents are more limited Our primary objective was to evaluate the frequency of patients receiving anti-PD-1 PD-L1 therapy for at least 6 continuous months who experienced new or worsening irAEs requiring clinical interventions





中文字典-英文字典  2005-2009